OAM
AIMT

Oxford Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Oxford Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-84,800
Closed -$1.78M – 2231
2019
Q3 		$1.78M Sell
84,800
-18,466
-18% -$377K 0.04% 618
2019
Q2 		$2.15M Buy
+103,266
New +$2.13M 0.05% 612
2018
Q3 		– Sell
-43,744
Closed -$1.17M – 2053
2018
Q2 		$1.17M Buy
+43,744
New +$1.34M 0.02% 942

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oxford Asset Management's AIMT Position: Q4 2019 in Review

Oxford Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 84,800 shares — an estimated $1.78M sold.

Oxford Asset Management first reported a position in AIMT in Q2 2018 and held it in 3 quarters. The position peaked at $2.15M in Q2 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Oxford Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 84,800 Aimmune Therapeutics shares in Q4 2019, an estimated $1.78M.
  • Oxford Asset Management first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 3 quarters.
  • Oxford Asset Management's Aimmune Therapeutics position peaked at $2.15M in Q2 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.